Eye Care

Merck sells eye business

Santen Pharmaceutical is buying limited rights to Merck's eye portfolio for $600 million and milestone payments.

Roche pursues a new eye-care angle

By

Squeezed in the wet AMD space, Roche could get some eye-care breathing room if it can snag first-to-market status in the dry AMD category. Early results bode well.

Email Newsletters

MM&M inVISION